Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer Guidelines


Authors: Kelly, R. J.; Bever, K.; Chao, J.; Ciombor, K. K.; Eng, C.; Fakih, M.; Goyal, L.; Hubbard, J.; Iyer, R.; Kemberling, H. T.; Krishnamurthi, S.; Ku, G.; Mordecai, M. M.; Morris, V. K. 2nd; Paulson, A. S.; Peterson, V.; Shah, M. A.; Le, D. T.
Title: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
Abstract: Gastrointestinal (GI) cancers, including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer, comprise a heterogeneous group of malignancies that impose a significant global burden. Immunotherapy has transformed the treatment landscape for several GI cancers, offering some patients durable responses and prolonged survival. Specifically, immune checkpoint inhibitors (ICIs) directed against programmed cell death protein 1 (PD-1), either as monotherapies or in combination regimens, have gained tissue site-specific regulatory approvals for the treatment of metastatic disease and in the resectable setting. Indications for ICIs in GI cancer, however, have differing biomarker and histology requirements depending on the anatomic site of origin. Furthermore, ICIs are associated with unique toxicity profiles compared with other systemic treatments that have long been the mainstay for GI cancer, such as chemotherapy. With the goal of improving patient care by providing guidance to the oncology community, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of GI cancer. Drawing from published data and clinical experience, the expert panel developed evidence- and consensus-based recommendations for healthcare professionals using ICIs to treat GI cancers, with topics including biomarker testing, therapy selection, and patient education and quality of life considerations, among others. © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Keywords: gastrointestinal neoplasms; guidelines as topic
Journal Title: Journal for ImmunoTherapy of Cancer
Volume: 11
Issue: 6
ISSN: 2051-1426
Publisher: Biomed Central Ltd  
Date Published: 2023-06-01
Start Page: e006658
Language: English
DOI: 10.1136/jitc-2022-006658
PUBMED: 37286304
PROVIDER: scopus
PMCID: PMC10254964
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Geoffrey Yuyat Ku
    231 Ku